<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01750905</url>
  </required_header>
  <id_info>
    <org_study_id>12-001869</org_study_id>
    <nct_id>NCT01750905</nct_id>
  </id_info>
  <brief_title>Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients</brief_title>
  <official_title>A Phase I, Randomized, Double-blind, Placebo-controlled, Crossover Study Evaluating The Safety, Hemodynamic And Neurohumoral Effects of a Novel Chimeric Peptide, CD-NP, in Patients With Left Ventricular Assist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The most promising chimeric natriuretic peptide designed and studied by our group has been&#xD;
      CD-NP which has anti-fibrotic and cardioprotective properties in vivo, vitro and in normal&#xD;
      volunteers and human heart failure patients. Since left ventricular assist device (LVAD) can&#xD;
      not reverse remodeling of the heart whereas it can improve hemodynamics, CD-NP may be novel&#xD;
      anti-fibrotic and anti-remodeling drug as co-therapy during LVAD support.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a double blind, placebo-controlled phase I trial of the safety and neurohumoral&#xD;
      activity of CD-NP, in the treatment of heart failure with LVAD support. Subjects more than 3&#xD;
      months after LVAD implantation will be screened at outpatient clinic visit appointments lists&#xD;
      and interested qualified subjects will be either confronted at a visit or sent a letter in&#xD;
      the mail to be consented and offered participation in this trial. Once consent has been&#xD;
      obtained, baseline values will be established at day 1 and subjects will be given&#xD;
      subcutaneous injection of placebo or CD-NP and stay overnight on two different visits in the&#xD;
      Clinical Research Unit (CRU). Participant's will receive both placebo and the CD-NP during&#xD;
      the study, one per visit. A final follow-up visit for clinical assessment will be conducted&#xD;
      over the phone at the end of the study.&#xD;
&#xD;
      Potential subjects who present to Mayo Clinic, Rochester, Minnesota for follow up clinical&#xD;
      visit after LVAD implantation will be identified by the study coordinator. A $300&#xD;
      remuneration per subject will be involved to compensate for the inconvenience to the subject.&#xD;
      A $500 reimbursement of gas mileage will be provided for those who travel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with Hypotension</measure>
    <time_frame>approx day 9</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean plasma Cyclic guanosine monophosphate (cGMP) level</measure>
    <time_frame>Approx day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean aldosterone level</measure>
    <time_frame>approx 9 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Left Ventricular Insufficiency</condition>
  <arm_group>
    <arm_group_label>CD-NP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CD-NP 5 ug/kg subcutaneous injection (SQ)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: Vehicle (D5W) SQ</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD-NP</intervention_name>
    <description>CD-NP 5 ug/kg subcutaneous injection (SQ)</description>
    <arm_group_label>CD-NP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vehicle (D5W) SQ</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Male and non-pregnant/post-menopausal female, ages 18-90, in end-stage Heart Failure&#xD;
             (HF) with LVAD support who are stable in the healed stage after at least 3 months from&#xD;
             the LVAD implant (Destination therapy only) (the post-menopausal state is defined as&#xD;
             the absence of menses for ≥ 1 year and serum follicle-stimulating hormone ≥ 20 IU/L;&#xD;
             sterilization in the female is defined as bilateral tubal occlusion for ≥ 6 months,&#xD;
             bilateral oophorectomy, or complete hysterectomy)&#xD;
&#xD;
          -  Be willing to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Known allergy or other adverse reactions to exogenous natriuretic peptides (CD-NP or&#xD;
             its components, nesiritide, other natriuretic peptides, or related compounds).&#xD;
&#xD;
          -  Women who are pregnant, or breast-feeding.&#xD;
&#xD;
          -  Having received nesiritide within 7 days prior to prior to entry into the study.&#xD;
&#xD;
          -  Having received any investigational drug or device within 30 days prior to entry into&#xD;
             the study.&#xD;
&#xD;
          -  Clinically unstable patients (e.g. mean blood pressure &lt; 70 mmHg, ongoing requirement&#xD;
             for vasopressors, or mechanical ventilation).&#xD;
&#xD;
          -  Recent hospitalization for decompensated HF or recent defibrillation for cardiac&#xD;
             resuscitation within 30 days prior to randomization.&#xD;
&#xD;
          -  Patients with guarded prognosis who are unlikely to derive meaningful benefit from&#xD;
             CD-NP.&#xD;
&#xD;
          -  Use of sulfonamides, non-steroidal anti-inflammatory drugs, probenecid, or other drugs&#xD;
             that are known to alter renal function within one week of the first dose of CD-NP or&#xD;
             placebo.&#xD;
&#xD;
          -  Presence of cardiac lesions or comorbidities that may contraindicate the use of&#xD;
             natriuretic peptides, such as clinically significant cardiac valvular stenosis,&#xD;
             hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis,&#xD;
             primary pulmonary hypertension, or uncorrected congenital heart disease that&#xD;
             contraindicates the use of vasodilators.&#xD;
&#xD;
          -  Symptomatic carotid artery disease, known critical carotid stenosis, or stroke within&#xD;
             the past 3 months&#xD;
&#xD;
          -  Clinically significant renal artery stenosis&#xD;
&#xD;
          -  Baseline hemoglobin &lt; 9.0 g/dl.&#xD;
&#xD;
          -  Serum sodium &lt; 130 mEq/L, potassium &lt; 3.6 milliequivalents per Liter (mEq/L), or&#xD;
             magnesium &lt; 1.5 mEq/L.&#xD;
&#xD;
          -  Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) at least 5&#xD;
             times the upper limit of normal or bilirubin at least 5 times the upper limit of&#xD;
             normal&#xD;
&#xD;
          -  Creatinine clearance (CrCl) &lt; 30 ml.min-1.1.73m-2, as calculated by Cockcroft-Gault&#xD;
             formula(35) and adjusted for body surface area within 3 months or at screening, or&#xD;
             requirement for dialysis.&#xD;
&#xD;
          -  History of alcohol or drug abuse within the past 6 months.&#xD;
&#xD;
          -  Inability to communicate effectively with study personnel.&#xD;
&#xD;
          -  BMI &gt;40&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Schirger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>December 13, 2012</study_first_submitted>
  <study_first_submitted_qc>December 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2012</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>John A. Schirger</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

